Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects 12 years of age and older~* Provide written informed consent/pediatric assent. If the subject is a minor, parent or legal guardian must give written informed consent~* Subjects must have moderate-to-severe rhinitis, defined as having one or more of the following:~  1. Sleep disturbance~ 2. Impairment of daily activities, leisure and/or sport~ 3. Impairment of school or work~ 4. Troublesome symptoms~* Screening Visit: Have a 12-hour reflective TNSS of at least 8 of 12 and a congestion score of 2 or 3 on Visit 1~* Randomization Visit: Have a 12-hour reflective TNSS (AM or PM) of at least 8 on 3 separate symptom assessments (one of which was within 2 days of Day 1, and can include the morning of Day 1) during the Lead-in Period.~* Randomization Visit: Have an AM or PM 12-hour reflective nasal congestion score of 2 or 3 must have been recorded on 3 separate symptom assessments (one of which was within 2 days of Day 1, and can include the morning of Day 1) Randomization Visit: Have an instantaneous TNSS score of 8 or more at time point zero, just prior to beginning the onset of action assessment~* Have taken at least 10 doses of the lead-in medication~* Willing and able to comply with the study requirementsAt least a 2-year history of SAR during Fall allergy season~* The presence of IgE-mediated hypersensitivity to a local Fall pollen, confirmed by a positive response to skin prick within the last year. A positive response is defined as a wheal diameter of at least 3 mm larger than the negative control.~* General good health and free of disease or concomitant treatment that could interfere with the interpretation of the study results~* Subjects receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit~* Subjects currently receiving sublingual immunotherapy are excluded. A 6-month washout period is required following the last dose of sublingual immunotherapy.~Exclusion Criteria:~* On Focused Nasal Examination, the presence of any superficial and moderate nasal mucosal erosion, nasal mucosal ulceration, or nasal septum perforation at either the screening visit or randomization visit~* Other nasal disease(s) likely to affect deposition of intranasal medication~* Nasal surgery or sinus surgery within the previous year.~* Chronic sinusitis - more than 3 episodes per year~* Planned travel outside of the pollen area during the study period~* The use of any investigational drug within 30 days prior to Day -7.~* Presence of any hypersensitivity to drugs similar to azelastine hydrochloride or fluticasone propionate~* Women who are pregnant or nursing~* Women of childbearing potential who are not abstinent or not practicing a medically acceptable method of contraception\*~* Respiratory Tract Infections within 14 days prior to Day -7~* Respiratory Tract Infections requiring antibiotic treatment 14 days prior to Day -7~* Asthma (with the exception of intermittent asthma).~* Significant pulmonary disease including COPD~* Clinically significant arrhythmia or symptomatic cardiac conditions~* A known history of alcohol or drug abuse within the last 2 years~* Existence of any surgical or medical condition or physical or laboratory findings that could interfere with study result interpretation.~* Patients with a history of Glaucoma~* Clinically relevant abnormal physical findings within 1 week of randomization that may preclude compliance with the study procedures~* Employees of the research center or private practice and their family members are excluded~* Subjects who participated in protocol MP4001 or MP4002

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- azelastine HCl/fluticasone propionate (Type: EXPERIMENTAL): nasal spray
- azelastine HCL (Type: ACTIVE_COMPARATOR): nasal spray
- fluticasone propionate (Type: ACTIVE_COMPARATOR): nasal spray
- placebo (Type: PLACEBO_COMPARATOR): nasal spray

Based on this trial design, predict the completion outcome and termination type (if applicable).